In summary, our study showed that the inhibition of XBP1s by FT@XBP1 could restore the integrity of the intestinal mucosal barrier and intestinal flora disturbance and inhibit LPS translocation, which subsequently reduces liver inflammation and lipid deposition and prevents NASH progression. Here, XBP1 is linked to metabolic dysfunction-associated steatohepatitis.